Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.51 |
| ▸ | CNR2 | P34972 | 5/20 | 0.47 |
| ▸ | CNR1 | P21554 | 4/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5154580 | 0.83 | ICMT (0.55) | SCN9ACNR2CNR1KMT2AALDH1A1 | |
| SCHEMBL5151526 | 0.83 | SCN9A (0.49) | SCN9AKMT2AALDH1A1MAPTRECQL | |
| SCHEMBL5149260 | 0.82 | SCN9A (0.53) | SCN9AKMT2AALDH1A1MAPTRECQL | |
| SCHEMBL4613529 | 0.82 | SCN9A (0.53) | SCN9AKMT2AALDH1A1MAPTRECQL | |
| SCHEMBL5156070 | 0.82 | SCN9A (0.53) | SCN9AKMT2AALDH1A1MAPTRECQL | |
| SCHEMBL5151102 | 0.81 | SCN9A (0.57) | SCN9AALDH1A1MAPT | |
| SCHEMBL5155704 | 0.81 | ICMT (0.62) | SCN9ACNR2CNR1 | |
| SCHEMBL5154481 | 0.81 | ICMT (0.62) | SCN9ACNR2CNR1 | |
| SCHEMBL5151092 | 0.80 | USP2 (0.51) | SCN9ACNR2KMT2AALDH1A1MAPT | |
| SCHEMBL1661389 | 0.79 | GPR84 (0.57) | SCN9AALDH1A1MAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060573-A1 | Acyltryptophanols | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060573-A1 | Acyltryptophanols | FSHR, NPY1R, NPY2R | SCN9A 3913/4885CNR2 127/4885CNR1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.